Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).

T, Yamamoto; T, Fujii; S, Hirano; F, Motoi; G, Honda; K, Uemura; J, Kitayama; M, Unno; Y, Kodera; H, Yamaue; T, Shimokawa; D, Hashimoto; S, Yamaki; H, Yoshitomi; F, Miura; H, Ueno; M, Sekimoto; S, Satoi

doi:10.1186/s13063-022-06049-7

Public

Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).

Shared by NobleBlocks on Feb 5, 2022 • 12:00 AM UTC

Authors:

Yamamoto T

Fujii T

Hirano S

Abstract

The prognosis of pancreatic ductal carcinoma (PDAC) with peritoneal metastasis remains dismal. Systemic chemotherapy alone may not be effective, and the combination of intraperitoneal chemotherapy with systemic chemotherapy is expected to prolong the overall survival in patients with peritoneal meta...

Subject

Peritoneal Metastasis

Pancreatic Ductal Carcinoma

Intraperitoneal Paclitaxel

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!